Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 1;56(5):828-838.
doi: 10.1249/MSS.0000000000003374. Epub 2024 Jan 18.

Prevalence of Drug Use in Ultraendurance Athletes

Paul Robach, Gilles Trebes  1 , Corinne Buisson  2 , Nathalie Mechin  2 , Monica Mazzarino  3 , Flaminia Garribba  3 , Matthieu Roustit, Jean-Louis Quesada  4 , Brice Lefèvre  5 , Guido Giardini  6 , Sophie DE Seigneux  7 , Francesco Botré, Pierre Bouzat  8
Affiliations

Prevalence of Drug Use in Ultraendurance Athletes

Paul Robach et al. Med Sci Sports Exerc. .

Abstract

Purpose: In competitive sport, classic methods of measuring drug prevalence, such as doping controls or questionnaires, are challenging. Here we describe a novel urine sampling method to measure drug use in athletes. We hypothesize that the prevalence of drug use in ultramarathon runners is measured more accurately with our sampling method than randomized-response questionnaires.

Methods: Urine samples and associated demographic data were collected from male participants using blind, automated urinals at the start of ultramarathon races. Various nonprohibited and prohibited substances were subsequently screened. Concomitantly, 2931 male and female runners participating in the same ultramarathons completed an anonymized, randomized-response questionnaire regarding drug use.

Results: Among 412 individual urine samples, 205 (49.8%) contained at least one substance, and 16.3% of the samples contained one or more prohibited substances. Substances detected in urine included nonsteroid anti-inflammatory drugs (NSAID) (22.1%), acetaminophen (15.5%), opioids (6.6%), diuretics (4.9%), hypnotics (4.4%), glucocorticoids (2.7%), beta-2 agonists (2.2%), cannabinoids (1.9%), and stimulants (1.2%). None of the samples contained erythropoietin-receptor agonists or suspicious testosterone. Drug use was not associated with the participants' characteristics or ranking. Respondents to the questionnaire reported using acetaminophen (13.6%) and NSAID (12.9%); however, no prohibited substances were declared.

Conclusions: There was a high prevalence of drug use among male ultramarathon runners, in particular, NSAID and painkillers; however, performance-enhancing drugs were marginally used. Blind urine sampling highlighted prohibited drug use not declared in questionnaires, and it is useful to assess the prevalence of drug use and/or doping in competitive athletes.

Trial registration: ClinicalTrials.gov NCT03402022.

PubMed Disclaimer

References

    1. de Hon O, Kuipers H, van Bottenburg M. Prevalence of doping use in elite sports: a review of numbers and methods. Sports Med . 2015;45(1):57–69.
    1. World Anti-Doping Agency website. Anti-doping Rule Violations (ADRVS) Report . Montréal (Canada): World Anti-Doping Agency. Available from: https://www.wada-ama.org/sites/default/files/2023-05/2020_adrv_report.pdf . Accessed October 24, 2023.
    1. Faiss R, Saugy J, Zollinger A, et al. Prevalence estimate of blood doping in elite track and field athletes during two major international events. Front Physiol . 2020;11:160.
    1. Sottas PE, Robinson N, Fischetto G, Dolle G, Alonso JM, Saugy M. Prevalence of blood doping in samples collected from elite track and field athletes. Clin Chem . 2011;57(5):762–9.
    1. Ulrich R, Pope HG Jr., Cleret L, et al. Doping in two elite athletics competitions assessed by randomized-response surveys. Sports Med . 2018;48(1):211–9.

Substances

Associated data